Benzinga · Nov 10, 2026
TD Cowen Maintains Hold on Quanterix, Raises Price Target to $4
TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and raises the price target from $3.5 to $4.
QT
NASDAQ · QTRX
Quanterix Corporation
Healthcare · Medical - Devices
$2.93
Up+$0.07 (+2.45%)
Updated Nov 15, 2026, 10:15 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 352.9M
- P/E ratio
- -4.17
- Dividend yield
- 0.00%
- 52-week range
- $2.15 – $8.77
- Volume
- 394.29K
- Avg. volume
- 639.37K
Price performance · QTRX
QTRX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
QTRX closed at $2.93 after 20 trading sessions, up 5.78% for the selected period.
- Last close
- $2.93
- Period change
- +5.78%
- Period low
- $2.72
- Period high
- $3.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $2.90 | $3.035 | $2.78 | $2.93 | 394.29K |
| Nov 12, 2026 | $2.98 | $3.10 | $2.855 | $2.86 | 622.05K |
| Nov 11, 2026 | $3.33 | $3.40 | $2.985 | $3.02 | 507.09K |
| Nov 10, 2026 | $3.42 | $3.53 | $3.18 | $3.28 | 741.11K |
| Nov 9, 2026 | $2.91 | $3.44 | $2.8272 | $3.38 | 1.18M |
| Nov 6, 2026 | $2.81 | $2.93 | $2.78 | $2.895 | 474.78K |
| Nov 5, 2026 | $3.01 | $3.01 | $2.715 | $2.76 | 357.36K |
| Nov 4, 2026 | $2.99 | $3.13 | $2.925 | $3.04 | 402.18K |
| Nov 3, 2026 | $2.87 | $2.98 | $2.87 | $2.94 | 266.87K |
| Nov 2, 2026 | $2.94 | $2.94 | $2.735 | $2.81 | 513.37K |
| Oct 30, 2026 | $3.10 | $3.105 | $2.83 | $2.905 | 361.3K |
| Oct 29, 2026 | $3.11 | $3.21 | $3.095 | $3.145 | 334.19K |
| Oct 28, 2026 | $2.87 | $3.12 | $2.84 | $3.12 | 658.74K |
| Oct 27, 2026 | $2.86 | $2.96 | $2.82 | $2.89 | 467.7K |
| Oct 26, 2026 | $2.86 | $2.896 | $2.79 | $2.83 | 257.08K |
| Oct 23, 2026 | $2.82 | $2.88 | $2.71 | $2.86 | 349.8K |
| Oct 22, 2026 | $2.74 | $2.895 | $2.71 | $2.84 | 496.29K |
| Oct 21, 2026 | $2.71 | $2.815 | $2.675 | $2.79 | 525.25K |
| Oct 20, 2026 | $2.77 | $2.845 | $2.71 | $2.72 | 536.49K |
| Oct 19, 2026 | $2.87 | $2.93 | $2.72 | $2.77 | 430.15K |
Latest QTRX news
The latest Smart Investors Daily articles mentioning QTRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
QTRX research
Overview
Company profile and research snapshot.
Company profile
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 10, 2026 | TD Cowen | Hold | — |
| Oct 13, 2026 | TD Cowen | Hold | — |
| Aug 17, 2026 | Canaccord Genuity | Hold | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| May 7, 2026 | TD Cowen | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 9, 2026
Quanterix Corp (QTRX) Q3 2026 Earnings Call Transcript
Sequential growth returned, but year-over-year comparisons remain challenging.
Yahoo · Nov 9, 2026
Quanterix Corporation Q3 2026 Earnings Call Summary
Moby summary of Quanterix Corporation's Q3 2026 earnings call
Yahoo · Nov 9, 2026
What Quanterix (QTRX) Said on Its Q3 Earnings Call
Quanterix (NASDAQ:QTRX) reported third-quarter revenue of $35 million, up 6.3% from the previous quarter but down 13.1% from a year earlier, as stronger spatial consumables sales helped the company exceed its own expectations. President and CEO Everett Cunningham said the results marked an early st
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
